Guidelines for the Diagnosis of Autoimmune Hepatitis

Diagnostic Work‑up Overview

• A systematic diagnostic approach that combines specific autoantibody testing, serum IgG measurement, liver function tests, exclusion of alternative liver diseases, and a mandatory liver biopsy is required for definitive diagnosis of autoimmune hepatitis (AIH). 1, 2

Initial Laboratory Assessment

Liver Function Tests

• Serum aminotransferases (AST/ALT) are typically markedly elevated, ranging from just above the normal limit to more than 50 times the upper limit of normal, while alkaline phosphatase and bilirubin are usually normal or only mildly increased, producing a hepatitic pattern. 3, 1, 2

Immunoglobulin G (IgG)

• Serum IgG (or gamma‑globulin) is elevated to >1.5 × the upper normal limit in approximately 85 % of patients with AIH. 3, 1, 2
• Normal IgG does not exclude AIH; 10–25 % of cases—particularly acute presentations—may have IgG within the normal range. 2

Autoantibody Testing Protocol

First‑Line Screening (Type 1 AIH)

• Antinuclear antibody (ANA) and smooth muscle antibody (SMA) are screened by indirect immunofluorescence; a titer ≥ 1:40 in adults (≥ 1:20 in children) is considered significant. 3, 1, 2
• Approximately two‑thirds of AIH patients display a homogeneous ANA pattern. 1

Second‑Line Testing (Type 2 AIH)

• Anti‑liver kidney microsomal type 1 (anti‑LKM1) and anti‑liver cytosol type 1 (anti‑LC1) antibodies identify Type 2 AIH and are present in 5–10 % of adult patients. 3, 1, 2

Additional Autoantibodies

• Anti‑soluble liver antigen (anti‑SLA) is the only antibody that is truly specific for AIH and is linked to a more severe disease phenotype. 1, 2
• Atypical perinuclear anti‑neutrophil cytoplasmic antibodies (pANCA) may be assessed when other autoantibodies are negative; a positive result requires exclusion of primary sclerosing cholangitis and inflammatory bowel disease. 1

Exclusion of Alternative Diagnoses

Viral Hepatitis

• Testing for hepatitis A, B, C, D, and E is mandatory; negative viral serologies add points to the AIH diagnostic scoring system. 3, 4, 1, 2

Drug‑Induced Liver Injury (DILI)

• A thorough medication history—including agents such as nitrofurantoin, minocycline, α‑methyldopa, hydralazine, and herbal/dietary supplements—is essential because DILI can mimic AIH with positive autoantibodies and elevated IgG. 3, 4

Alcohol and Other Liver Diseases

• Alcohol consumption < 25 g/day supports an AIH diagnosis. 3
• Hepatobiliary imaging (ultrasound and/or cross‑sectional imaging) should be performed to exclude biliary obstruction, cholecystitis, and hepatic vein thrombosis. 4
• Targeted testing for Wilson’s disease (ceruloplasmin), hereditary hemochromatosis (iron studies), and α‑1 antitrypsin deficiency is indicated when the clinical context suggests these disorders. 3, 1

Liver Biopsy – Mandatory for Diagnosis

• Liver biopsy cannot be omitted; histology is required to confirm AIH and to rule out alternative etiologies. 1, 2

Key Histological Features

• Moderate‑to‑severe interface hepatitis with lymphoplasmacytic infiltrates extending from portal tracts into hepatic lobules. 3, 1, 2
• Clusters of plasma cells—characteristic but not pathognomonic. 1, 2
• Hepatocyte rosetting (emperipolesis). 1
• Absence of biliary lesions, granulomas, or other changes suggestive of alternative diagnoses. 3

Timing

• Biopsy should be performed before initiating immunosuppressive therapy to confirm diagnosis, assess disease severity and stage (including cirrhosis), and exclude other entities. 1, 2

Diagnostic Scoring Systems

Simplified Scoring (Recommended for Clinical Practice)

• Autoantibodies: ANA or SMA ≥ 1:40 = 1 point; ≥ 1:80 = 2 points; anti‑LKM1 ≥ 1:40 = 2 points; anti‑SLA positive = 2 points.
• IgG: >ULN = 1 point; >1.1 × ULN = 2 points.
• Histology: compatible = 1 point; typical = 2 points.
• Viral hepatitis exclusion: 2 points.
• Interpretation: ≥ 6 points = probable AIH; ≥ 7 points = definite AIH. 1

Note on Serology

• Up to 5 % of AIH patients may be seronegative; therefore, diagnosis must not rely solely on autoantibody positivity. (Evidence level not specified in cited source.)

IgG Normality Caveat

• Normal IgG does not rule out AIH; 10–39 % of patients—especially those with acute onset—may have normal IgG levels. 2

Monitoring After Diagnosis

• Patients with established cirrhosis should undergo liver ultrasound every six months for hepatocellular carcinoma surveillance. 3

All statements are derived from peer‑reviewed sources indicated by the citation IDs; strength of evidence was not explicitly provided in the cited literature.

Autoimmune Hepatitis Diagnostic Approach

Initial Evaluation

• The American Association for the Study of Liver Diseases recommends a combination of autoantibody testing, immunoglobulin levels, liver function tests, and liver biopsy for the diagnostic workup of autoimmune hepatitis (AIH), with liver biopsy being essential for definitive diagnosis and treatment decisions 5, 6
• Liver function tests typically show a predominantly hepatitic pattern with elevated aminotransferases (ALT/AST) ranging from just above normal to >50 times normal, with normal or only moderately elevated cholestatic enzymes 7, 8
• Immunoglobulin assessment reveals hypergammaglobulinemia (elevated IgG) in approximately 85% of patients, though may be normal in 10-25% of cases, particularly in acute presentations 7, 9
• Initial autoantibody screening should include antinuclear antibody (ANA), smooth muscle antibody (SMA), anti-liver kidney microsomal type 1 antibody (anti-LKM1), and anti-soluble liver antigen (anti-SLA/LP) 5, 10, 6
• Viral hepatitis markers must be excluded, including hepatitis A, B, and C infection 7, 8

Autoantibody Testing Protocol

• Indirect Immunofluorescence (IFL) is the preferred initial screening method for ANA, SMA, and anti-LKM1 using rodent tissue sections 5, 10
• Significant titers in adults are ≥1:40 dilution by IFL; in children, titers of 1:20 for ANA/SMA and 1:10 for anti-LKM1 are significant 9
• ELISA or immunoblotting should be used for anti-SLA/LP detection, as IFL cannot detect these antibodies 10, 9, 5

Liver Biopsy and Diagnostic Criteria

• Liver biopsy is mandatory for definitive diagnosis, assessment of disease severity, and treatment decisions 5, 6
• The International Autoimmune Hepatitis Group's Simplified Diagnostic Criteria include autoantibodies, IgG levels, liver histology, and absence of viral hepatitis, with a score of ≥6 points indicating probable AIH and ≥7 points indicating definite AIH 11, 12, 5, 6, 9

Monitoring and Pitfalls

• Biochemical remission is defined as normalization of both transaminases and IgG levels 9
• Combined ALT and IgG measurements provide the best non-invasive monitoring of disease activity 9
• Overlooking AIH in viral hepatitis-endemic areas, relying solely on autoantibody testing, missing AIH with normal IgG levels, and failure to obtain liver biopsy are common pitfalls to avoid 9, 5, 10, 6

Diagnostic Workup for Autoimmune Hepatitis

Initial Laboratory Testing

• The International Autoimmune Hepatitis Group (IAIHG) recommends that the initial evaluation include a complete liver panel (AST, ALT, alkaline phosphatase, bilirubin, albumin), serum IgG measurement, and viral hepatitis serologies (HAV, HBV, HCV, HDV, HEV) to establish baseline hepatic function and exclude infectious causes. 13
• Serum IgG levels are typically elevated >1.5 × the upper limit of normal in the majority of patients, but a normal IgG does not rule out disease, especially in acute presentations. 14

Autoantibody Assessment

• ANA or SMA titers ≥ 1:40 in adults (≥ 1:20 in children) are considered significant for autoimmune hepatitis; higher titers (≥ 1:80) receive greater diagnostic weight. 13
• Anti‑LKM1 positivity (≥ 1:40) identifies type 2 autoimmune hepatitis, which accounts for 5–10 % of adult cases. 13
• Anti‑SLA/LP positivity is highly specific for autoimmune hepatitis and is associated with more severe disease. 13

Exclusion of Alternative Diagnoses

• Negative viral hepatitis markers are required for the diagnosis and contribute points to the IAIHG diagnostic scoring system. 13
• A detailed medication history should be obtained to identify drugs (e.g., nitrofurantoin, minocycline, α‑methyldopa, hydralazine, isoniazid, propylthiouracil, herbal supplements) that can cause drug‑induced hepatitis mimicking autoimmune hepatitis. 13
• Serum ceruloplasmin measurement is advised to exclude Wilson disease in patients < 40 years; α‑1 antitrypsin phenotype testing and iron studies (serum iron, ferritin, transferrin saturation) are recommended to rule out α‑1 antitrypsin deficiency and hereditary hemochromatosis, respectively. 13
• Documented daily alcohol intake < 25 g supports the diagnosis of autoimmune hepatitis. 13

Imaging Studies

• In acute severe presentations, unenhanced CT of the liver may reveal heterogeneous hypoattenuated areas in approximately 65 % of cases, aiding differentiation from other causes of acute liver failure. 14

Liver Biopsy (Mandatory)

• The IAIHG states that liver biopsy is essential for confirming autoimmune hepatitis, assessing disease stage (including cirrhosis), and excluding alternative diagnoses; it should not be omitted. 13
• Biopsy should be performed before initiating immunosuppressive therapy unless the patient has fulminant liver failure requiring immediate treatment. 14
• Histologic hallmark: interface hepatitis with lymphoplasmacytic infiltrates extending from portal tracts into hepatic lobules. 13
• Portal plasma‑cell infiltration is characteristic but not obligatory for diagnosis. 13
• Absence of biliary lesions, granulomas, or steatosis helps exclude overlap syndromes (primary sclerosing cholangitis, primary biliary cholangitis) and other liver diseases. 13
• Findings suggesting alternative etiologies:
  
  • Ductopenia or destructive cholangitis → overlap with cholestatic diseases. 13
  • Steatosis or iron overload → possible non‑alcoholic fatty liver disease, Wilson disease, or hemochromatosis. 13
  • Centrilobular hemorrhagic necrosis → typical of acute severe (fulminant) autoimmune hepatitis. 14

Common Pitfalls

• Up to 5 % of patients with autoimmune hepatitis may be seronegative for conventional autoantibodies; reliance on autoantibody positivity alone can miss cases. (Evidence from IAIHG consensus) 13
• Normal IgG levels occur in 25–39 % of acute presentations; clinicians should not exclude the disease based solely on IgG. 14
• Serum aminotransferase and gamma‑globulin levels do not reliably predict histologic severity or the presence of cirrhosis; liver biopsy remains indispensable. 13
• Drug‑induced hepatitis can mimic autoimmune hepatitis with positive autoantibodies and elevated IgG; thorough medication review is essential. 13
• In acute severe disease, performing a biopsy when feasible is critical because centrilobular hemorrhagic necrosis with lymphoplasmacytic infiltration distinguishes autoimmune hepatitis from viral or toxic acute liver failure. 14

Post‑Diagnosis Surveillance

• For patients with established cirrhosis, the IAIHG recommends liver ultrasound every six months for hepatocellular carcinoma surveillance. 14